{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:08:11Z","timestamp":1791266891330,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001747.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000}}],"reference-count":139,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001747.pub3","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T04:08:27Z","timestamp":1137730107000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Galantamine for Alzheimer's disease and mild cognitive impairment"],"prefix":"10.1002","volume":"2009","author":[{"given":"Clement","family":"Loy","sequence":"first","affiliation":[{"name":"Garvan Institute of Medical Research; Level 7; 384 Victoria St Darlinghurst NSW Australia 2010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon","family":"Schneider","sequence":"additional","affiliation":[{"name":"University of Southern California Keck School of Medicine; 1510 San Pablo St, HCC 600 Los Angeles CA USA 90033"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"10.1002\/14651858.CD001747.pub3-BIB0001|cit1","first-page":"661","article-title":"Galanthamine hydrobromide: Interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer Type","volume-title":"Alzheimer's Disease: Biology, Diagnosis and Therapeutics","author":"Wilcock","year":"1997"},{"issue":"9","key":"10.1002\/14651858.CD001747.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0003|cit3","unstructured":"Kristensen M Richardson A Van Osselaer N Vangeneugden T Morrison S Fleet D Lilienfeld S Truyen L Parys W A Europan multicentre placebo-controlled trial to determine the safety and efficacy of galantamine hydrobromide 40mg\/d (32mg\/d GAL bas, tid dose regimen) in patients diagnosed with Alzheimer-type dementia (GAL 95-05) Janssen Research Foundation 1997"},{"issue":"7278","key":"10.1002\/14651858.CD001747.pub3-BIB0005|cit4","first-page":"90","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))","volume":"322","author":"Wilcock","year":"2001","journal-title":"BR-MED-J: British-Medical-Journal"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0006|cit5","doi-asserted-by":"crossref","unstructured":"Wilcock GK GALANTAMINE ALLEVIATES CAREGIVER BURDEN IN ALZHEIMER'S DISEASE: A 6-MONTH PLACEBO-CONTROLLED STUDY Conference Proceedings World Alzheimer Congress; 9-13 July, 2000, Washington 2000","DOI":"10.1016\/S0197-4580(00)83423-5"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0004|cit6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"British Medical Journal"},{"issue":"2-3","key":"10.1002\/14651858.CD001747.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer's Disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0008|cit8","unstructured":"GAl-INT-11 A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Subjects With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer\u2019s Disease http:\/\/www.clinicalstudyresults.org\/documents\/ 2004"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0009|cit9","unstructured":"GAL-INT-18 A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Subjects With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer\u2019s Disease http:\/\/www.clinicalstudyresults.org\/documents\/ 2004"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0012|cit12","unstructured":"Erkinjuntti T Kurz A Gauthier S Bullock R Lilienfeld S Damaraju CV The safety and efficacy of Galantamine in the treatment of vascular and mixed dementia (Double-blind part only). (GAL-INT-6) Johnson and Johnson Pharmaceutical Research & Development. January 2004"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galamtine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"issue":"3S","key":"10.1002\/14651858.CD001747.pub3-BIB0015|cit15","first-page":"130S","article-title":"Galantamine, a selective non-toxic acetylcholinesterase inhibitor is significantly superior over placebo in treatment of SDAT","volume":"10","author":"Kewitz","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001747.pub3-BIB0016|cit16","first-page":"569","article-title":"New Alzheimer's drug is first therapy to show efficacy in vascular dementia","volume":"36","author":"Anon","year":"2001f","journal-title":"Formulary"},{"issue":"7153","key":"10.1002\/14651858.CD001747.pub3-BIB0017|cit17","first-page":"842","article-title":"Galantamine effective in treating dementia in patients with cerebrovascular disease","volume":"266","author":"Anon","year":"2001g","journal-title":"Pharmaceutical Journal"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.159","article-title":"Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition","volume":"50","author":"Bickel","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0019|cit19","unstructured":"Bores GM Huger F Petko W Mutlib A Camacho F Selk D Taberna V Kosley R Davis L Vargas H Evaluation of P11012 and P11149 for the treatment of Alzheimer's disease Third International Springfield Symposium on Advances in Alzheimer's Therapy Springfield IL 114"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001747.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1041610203009189","article-title":"Galantamine in the treatment of vascular dementia","volume":"15","author":"Brashear","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2165\/00002512-199609010-00007","article-title":"Galanthamine","volume":"9","author":"Brodaty","year":"1996","journal-title":"Drugs and Aging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001747.pub3-BIB0022|cit22","first-page":"S59","article-title":"Galantamine shows promising results in alzheimer's disease with cerebrovascular components and probable vascular dementia (preliminary results)","volume":"187","author":"Bullock","year":"2001","journal-title":"Journal of Neuroscience"},{"issue":"1-2","key":"10.1002\/14651858.CD001747.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0024|cit24","unstructured":"Burke W Lilienfeld S Galantamine improves behaviour and relieves caregiver distress in Alzheimer's disease (AD), vascular dementia and AD with cerebrovascular disease Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002 Abstract No 428"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0025|cit25","first-page":"6","article-title":"To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?","volume":"2","author":"Caro","year":"2002","journal-title":"BMC neurology [electronic resource]"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0026|cit26","first-page":"i","article-title":"Clinical and cost effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease a rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S026646230200034X","article-title":"Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review","volume":"18","author":"Clegg","year":"2002","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1742-1241.2003.tb10467.x","article-title":"Galantamine: a review of its use in Alzheimer's disease and vascular dementia","volume":"57","author":"Corey Bloom","year":"2003","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease","volume":"49","author":"Coyle","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00019442-200303000-00004","article-title":"Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations","volume":"11","author":"Cummings","year":"2003","journal-title":"American journal of geriatric psychiatry official journal of the American Association for Geriatric Psychiatry, The"},{"issue":"3","key":"10.1002\/14651858.CD001747.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","article-title":"Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease","volume":"161","author":"Cummings","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0032|cit32","first-page":"59","article-title":"Galanthamine treatment in Alzheimer's disease","volume":"33","author":"Dal Bianco","year":"1991","journal-title":"J Neurol Transm Suppl"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S1092852900009378","article-title":"The clinical and safety of galantamine in the treatment of alzheimer's disease","volume":"9","author":"Dengiz","year":"2004","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0034|cit34","unstructured":"Doran MD A randomised 26 week double-blind placebo controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease National Research Register 2003"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(02)11451-6","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Reply","volume":"360","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1468-1331.2002.04455.x","article-title":"Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine","volume":"9","author":"Erkinjuntti","year":"2002","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2165\/00002512-199609010-00006","article-title":"Galanthamine","volume":"9","author":"Fulton","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0039|cit39","unstructured":"GAL-COG-3002 An Analysis of Mortality in Subjects Who Participated in Three Studies of Galantamine in Mild Cognitive Impairment (MCI) http:\/\/www.clinicalstudyresults.org\/ 2005"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0040|cit40","unstructured":"GAL-MCI-301 An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment http:\/\/www.clinicalstudyresults.org\/drugdetails\/ 2004"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1532-5415.2004.52303.x","article-title":"Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.","volume":"52","author":"Galasko","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0042|cit42","first-page":"18","article-title":"The Safety and Efficacy of an Extended-Release Formulation of Galantamine (Reminyl ER) in the Treatment of Alzheimer's Disease","volume":"25","author":"Gold","year":"2004","journal-title":"NeuroBiology of Aging"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0043|cit43","first-page":"472","article-title":"Galantamine In The Treatment of Patients With Mild Cognitive Impairment: Baseline Demographics and Psychometric Testing Results","volume":"25","author":"Gold","year":"2004","journal-title":"NeuroBiology of Aging"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0044|cit44","first-page":"263","article-title":"Long-term treatment with galantamine slows the disease progression of patients with alzheimer's disease","volume":"8","author":"Hager","year":"2004","journal-title":"The Journal of Nutrition, Health and Aging"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0045|cit45","unstructured":"Haworth J GAL-INT-11: a randomised placebo-controlled trial to evaluate the efficacy and safety of galantamine in patients with minimal cognitive impairment (MCI) clinically at risk for development of probable Alzheimer's disease National Research Register 2003b"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0046|cit46","unstructured":"Janssen Pharmaeuticals Reminyl: tablets and oral solution http:\/\/www.us.reminyl.com\/ 2005"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gps.1038","article-title":"A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease","volume":"19","author":"Jones","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11910-002-0036-z","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Kertesz","year":"2002","journal-title":"Current Neurology & Neuroscience Reports"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/978-1-4615-8149-9_25","article-title":"Galanthamine in Alzheimer's disease","volume-title":"Alzheimer's disease: Therapeutic strategies","author":"Kewitz","year":"1994"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1358\/dot.1997.33.4.425052","article-title":"Pharmacokinetics and metabolism of galanthamine","volume":"33","author":"Kewtiz","year":"1997","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0051|cit51","unstructured":"Kurz A The safety and efficacy of galantamine in the treatment of vascular and mixed dementia (double-blind part only) Protocol GAL-INT-6; phase 3 Johnson & Johnson Pharmaceutical research & development, L.L.C. 1998"},{"issue":"178 Suppl","key":"10.1002\/14651858.CD001747.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-0404.106.s178.5.x","article-title":"Non-cognitive benefits of galantamine (Reminyl(R)) treatment in vascular dementia","volume":"106","author":"Kurz","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-1331.2003.00677.x","article-title":"Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"10","author":"Kurz","year":"2003","journal-title":"European journal of neurology the official journal of the European Federation of Neurological Societies"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0197-4580(04)80679-1","article-title":"Tolerability, Safety and Efficacy In Patients With Alzheimer's Disease Who Are Switched From Donepezil to Galantamine","volume":"25","author":"Kurz","year":"2004","journal-title":"NeuroBiology of Aging"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0055|cit55","unstructured":"Lilienfeld S Papadopoulos G Galantamine alleviates caregiver burden in Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0056|cit56","unstructured":"Lyketsos K Reichman W Kershaw P Long-term cognitive benefits of galantamine in alzheimer disease using a responder analysis at 18.5 months Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 214"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00019442-200409000-00005","article-title":"Long-term outcomes of galantamine treatment in patients with Alzheimer disease","volume":"12","author":"Lyketsos","year":"2004","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2","article-title":"Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease","volume":"13","author":"MacGowan","year":"1998","journal-title":"Int J Geriat Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11910-002-0062-x","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Marder","year":"2002","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/sleep\/26.5.602","article-title":"Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine","volume":"26","author":"Markowitz","year":"2003","journal-title":"Sleep"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0061|cit61","unstructured":"Mintzer JE Yuan W Kershaw P Efficacy of galantamine in patients with alzheimer's disease (AD) with previous exposure to cholinesterase inhibitors Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2000 Dec 10-14, San Juan, Puerto Rico 2000"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0062|cit62","unstructured":"Mintzer J Kershaw P Galantamine provides cognitive and functional benefits over 12 months in patients with Alzheimer's disease Proceedings of the 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26, San Francisco 2001"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(02)11450-4","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Comment","volume":"360","author":"Moretti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0064|cit64","unstructured":"Morris JC Kershaw P Cognitive benefits of long-term, continuous galantamine treatment in patients with alzheimer disease Proceedings of the 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3-6, Geneva 2002 220"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.1997.33.4.425051","article-title":"Preclinical studies with galanthamine","volume":"3","author":"Mucke","year":"1997","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology","volume":"19","author":"Nordberg","year":"1998","journal-title":"Drug Safety"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0197-4580(04)81565-3","article-title":"Galantamine inthe Treatment of Patients with MildCognitive Impairment: Effect ofDiagnostic Type at Baseline","volume":"25","author":"Novak","year":"2004","journal-title":"NeuroBiology of Aging"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0068|cit68","first-page":"521","article-title":"Impact of ApoE Genotype on The Efficacy of Galantamine For The Treatment of Mild Cognitive Impairment","volume":"25","author":"Nye","year":"2004","journal-title":"NeuroBiology of Aging"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Orgogozo J Small G Hammond G Schwalen S Galantamine improves cognition and function in patients with very mild Alzheimer's disease 8th Congress of the European Federation of the Neurological Sciences. Paris, France. September 4-7, 2004 2004","DOI":"10.1016\/S0924-977X(04)80439-5"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0070|cit70","first-page":"30","article-title":"Treatment of the psychogenic form of sexual asthenia with Nivalin (Bulgarian)","volume":"25","author":"Paskov","year":"1974","journal-title":"Savrmed"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0071|cit71","unstructured":"Patterson CE Passmore AP Quinlan M Browne G Thompson C A 6 month open label study of the efficacy and tolerability of galantamine in patients with Alzheimers disease (AD) Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002 Abstract No 342"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0072|cit72","first-page":"307","article-title":"[Observation of effect on Alzheimer disease treated by Galanthamine hydrobromide capules]","volume":"14","author":"Ping","year":"2000","journal-title":"Practical Geriatrics"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0197-4580(04)80637-7","article-title":"Does Galantamine Therapy in Mild to Moderate Alzheimer's Disease Improve Behaviour?","volume":"25","author":"Rabheru","year":"2004","journal-title":"NeuroBiology of Aging"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0074|cit74","unstructured":"Rainer M Janoch P Reiss A Galanthamine treatment in Alzheimer's Disease: a preliminary evaluation of forty patients of forty patients. Canadian Journal of Neurological Sciences 1993 S177"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0075|cit75","unstructured":"Rainer M Galanthamine treatment in Alzheimer's disease - The identification of responders Neuropsychopharmacology 1994 215S"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1358\/dot.1997.33.4.425053","article-title":"Clinical studies with galantamine","volume":"33","author":"Rainer","year":"1997","journal-title":"Drugs of Today"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","article-title":"Galanthamine in Alzheimer's disease. A new alternative to tacrine?","volume":"7","author":"Rainer","year":"1997","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1002\/14651858.CD001747.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s007020100009","article-title":"Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics","volume":"108","author":"Rainer","year":"2001","journal-title":"Journal of neural transmission"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0079|cit79","unstructured":"Raskind M Peskind E Parys W Wessel T Galantamine produces long term cognitive and functional in patients with Alzheimer's disease Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 225"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-1781(94)90013-2","article-title":"Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep","volume":"51","author":"Riemann","year":"1994","journal-title":"Psychiatry Res"},{"issue":"suppl 1","key":"10.1002\/14651858.CD001747.pub3-BIB0081|cit81","article-title":"Cholinergic neurotransmission, REM sleep and depression","volume":"38","author":"Riemann","year":"1994","journal-title":"J Psychosom Res"},{"issue":"10","key":"10.1002\/14651858.CD001747.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/gps.1000","article-title":"The effects of galantamine treatment on caregiver time in Alzheimer's disease","volume":"18","author":"Sano","year":"2003b","journal-title":"International journal of geriatric psychiatry"},{"issue":"S2","key":"10.1002\/14651858.CD001747.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0197-4580(04)80905-9","article-title":"Effect of Galantamine Treatment on Brain Atrophy as Assessed by MRI in Patients with Mild Cognitive Impairment","volume":"25","author":"Scheltens","year":"2004","journal-title":"NeuroBiology of Aging"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0084|cit84","first-page":"262","article-title":"Effects of continuous, interrupted and delayed galantamine treatment of long-term cognitive function in patients with advanced-moderate alzheimer's disease","volume":"8","author":"Schwalen","year":"2004","journal-title":"The Journal of Nutrition, Health and Aging"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0085|cit85","first-page":"261","article-title":"Comparison of the effects of 24mg versus 16mg galantamine in patients with moderate alzheimer's disease","volume":"8","author":"Schwalen","year":"2004","journal-title":"The Journal of Nutrition, Health and Aging"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: a review of its use in Alzheimer's disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/00023210-200317120-00004","article-title":"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"17","author":"Small","year":"2003","journal-title":"CNS drugs"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1300\/J092v02n02_04","article-title":"Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome","volume":"2","author":"Snorrason","year":"1996","journal-title":"J Chronic Fatigue Syndr"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0089|cit89","unstructured":"Steiger-Baechler G Monsch AU Bertoli S Staehelin HB Discontinuation of Acetylcholinesterase-Inhibitors in Alzheimer's disease and itrs effects on cognitive functioning unknown 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001747.pub3-BIB0090|cit90","first-page":"A415","article-title":"The efficacy and tolerability of galantamine in alzheimer's disease a 5 month placebo controlled study with slow dose escalation","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","article-title":"Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo","volume":"46","author":"Thomsen","year":"1990","journal-title":"Life Sci"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0092|cit92","first-page":"46","article-title":"Galantamine hydrobromide in a long-term treatment of Alzheimer's disease","volume":"1","author":"Thomsen","year":"1990","journal-title":"Dementia"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF00316106","article-title":"Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans","volume":"39","author":"Thomsen","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0094|cit94","unstructured":"Truyen L Galantamine-New Clinical Studies Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer's Disease 2000 156"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0095|cit95","unstructured":"Truyen L Clinical implications for galantamine's nicotinic receptor modulation Proceedings of the Sixth International Stockholm\/Springfield Symposium on Advances in Alzheimer's Disease 2000 157"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0096|cit96","unstructured":"Truyen L Galantamine clinical implications for nicotinic receptor modulation. The second kuopio Alzheimer symposium, Kuopio Music Centre, Kuopio, Finland, March 13-15, 2001 2001 42"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub3-BIB0097|cit97","first-page":"1512","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial: comment","volume":"360","author":"Gool","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0098|cit98","first-page":"262","article-title":"Effects of galantamine on activities of daily living","volume":"8","author":"Vellas","year":"2004","journal-title":"The Journal of Nutrition, Health and Aging"},{"issue":"51-52","key":"10.1002\/14651858.CD001747.pub3-BIB0099|cit99","first-page":"31","article-title":"Acetylcholinesterase inhibitors: Galanthamine in Alzheimer's Dementia","volume":"137","author":"Wasielewski","year":"1997","journal-title":"Deutsche Apotheker Zeitung"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0100|cit100","first-page":"781","article-title":"Galanthamine and the treatment of Alzheimer's disease","volume":"8","author":"Wilcock","year":"1993","journal-title":"Int J Geriat Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0101|cit101","first-page":"16","article-title":"Reminyl (galantamine) alleviates caregiver burden in alzheimer's disease in two 6 month studies","volume":"1","author":"Wilcock","year":"2000i","journal-title":"Clinical Neuropsychological Assessment"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0102|cit102","first-page":"43","article-title":"Long term cognitive and functional benefits of reminyl (galantamine ) in patients with alzheimer's disease","volume":"1","author":"Wilcock","year":"2000j","journal-title":"Clinical Neuropsychological Assessment"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0103|cit103","unstructured":"Wilkinson D Lilienfeld S Truyen L Galantamine improves activities of daily living in patients with alzheimer's disease: A 3 month placebo-controlled study Proceedings of the 6th International Stockholm\/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden 2000 233"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ajhp\/60.5.446","article-title":"Galantamine hydrobromide: an agent for Alzheimer's disease","volume":"60","author":"Zarotsky","year":"2003","journal-title":"American journal of health system pharmacy AJHP official journal of the American Society of Health System Pharmacists"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0105|cit105","unstructured":"Not reported Ongoing study"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0106|cit106","unstructured":"The safety and efficacy of Galanthamine in the treatment of vascular and mixed dementia Ongoing study"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0107|cit107","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"issue":"2","key":"10.1002\/14651858.CD001747.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000067974","article-title":"Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months","volume":"15","author":"Blesa","year":"2003","journal-title":"Dementia and geriatric cognitive disorders"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in Treatment Assignment in Controlled Clinical Trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Eng J Med,"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0110|cit110","first-page":"i","article-title":"Clinical and cost effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease a rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"12","key":"10.1002\/14651858.CD001747.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0112|cit112","volume-title":"Treatment of early breast cancer: Worldwide evidence 1985-1990","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1990"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental State. A practical method for grading the cognitive status of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatry Research"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0115|cit115","unstructured":"Johnson Johnson GAL-COG-3002 www.clinicaltrials.org"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0116|cit116","unstructured":"Gutierrez R Kershaw P Wessel T Pontecorvo M Shnaidman M Chang S Safety and efficacy of galantamine during its withdrawal in the treatment of Alzheimer's Disease Jansseen Research Foundation 1998"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"10.1002\/14651858.CD001747.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia","volume":"53","author":"Gelinas","year":"1999","journal-title":"Am J Occup Ther"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1212\/WNL.57.6.972","article-title":"Assessment of health economics in Alzheimer's disease AHEAD galantamine treatment in canada","volume":"57","author":"Getsios","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0120|cit120","first-page":"218","article-title":"Clinical Global Impressions (CGI)","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0163-7258(95)02002-0","article-title":"The pharmacology of galanthamine and its analogues","volume":"68","author":"Harvey","year":"1995","journal-title":"Pharmac. Ther."},{"key":"10.1002\/14651858.CD001747.pub3-BIB0122|cit122","article-title":"The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines","volume-title":"World Health Organization","author":"World Health Organization","year":"1992"},{"issue":"1-3","key":"10.1002\/14651858.CD001747.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10799899709036592","article-title":"Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists.","volume":"17","author":"Maelicke","year":"1997","journal-title":"Journal-of-receptor-and-signal-transduction-research"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer\u2019s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"4","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001747.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0149-2918(03)80171-6","article-title":"Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the united states","volume":"25","author":"Migliaccio-Walle","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/gps.826","article-title":"The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure","volume":"18","author":"Mintzer","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(02)11450-4","article-title":"\"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial\": Comment","volume":"360","author":"Moretti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0128|cit128","article-title":"Cochrane Collaboration Handbook","volume-title":"Cochrane Collaboration Handbook [updated 9 December 1996] Available in The Cochrane Library [database on disk and CDROM], Issue 1","author":"Mulrow","year":"1997"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0129|cit129","first-page":"767","article-title":"Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetycholinesterase","volume":"274","author":"Pacheco","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0130|cit130","first-page":"939","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer's Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD001747.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1185\/030079904125003214","article-title":"Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease","volume":"20","author":"Stahl","year":"2004","journal-title":"Current medical research and opinion"},{"issue":"1","key":"10.1002\/14651858.CD001747.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(88)90325-5","article-title":"A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.","volume":"31","author":"Sweeney","year":"1988","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/BF00785549","article-title":"Interaction of reversible inhibitors with catalytic centres and allosteric site of cholinesterases","volume":"82","author":"Tonkopii","year":"1976","journal-title":"Bull. Exp. Bio. Med"},{"issue":"9344","key":"10.1002\/14651858.CD001747.pub3-BIB0136|cit136","first-page":"1512","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial: comment","volume":"360","author":"Gool","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001747.pub3-BIB0137|cit137","first-page":"562","article-title":"GALANTAMINE ALLEVIATES CAREGIVER BURDEN IN ALZHEIMER\u00a2S DISEASE: A 6-MONTH PLACEBO-CONTROLLED STUDY","volume":"15","author":"Wilcock","year":"2000","journal-title":"Conference Proceedings World Alzheimer Congress; 9-13 July, 2000; Washington"},{"issue":"7278","key":"10.1002\/14651858.CD001747.pub3-BIB0138|cit138","first-page":"90","article-title":"Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))","volume":"322","author":"Wilcock","year":"2001","journal-title":"BR-MED-J: British-Medical-Journal"},{"issue":"7","key":"10.1002\/14651858.CD001747.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1742-1241.2002.tb11310.x","article-title":"Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months","volume":"56","author":"Wilkinson","year":"2002","journal-title":"International Journal of Clinical Practice"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001747.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001747.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T07:03:25Z","timestamp":1683356605000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001747.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001747.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001747.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,25]]}}}